Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein

被引:149
作者
Ekins, S
Kim, RB
Leake, BF
Dantzig, AH
Schuetz, EG
Lan, LB
Yasuda, K
Shepard, RL
Winter, MA
Schuetz, JD
Wikel, JH
Wrighton, SA
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Vanderbilt Univ, Div Clin Pharmacol, Nashville, TN USA
[3] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
关键词
D O I
10.1124/mol.61.5.964
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules. A better understanding of the structural requirements of modulators of P-gp function will aid in the design of therapeutic agents. Toward this goal, three-dimensional quantitative structure-activity relationship (3D-QSAR) models were generated using in vitro data associated with inhibition of P-gp function. Several approaches were undertaken with multiple iterations, yielding Catalyst 3D-QSAR models being able to qualitatively rank-order and predict IC50 values for P-gp inhibitors excluded from the model in question. The success of these validations suggests that a P-gp pharmacophore for 27 inhibitors of digoxin transport in Caco-2 cells consisted of four hydrophobes and one hydrogen bond acceptor. A second pharmacophore generated with 21 inhibitors of vinblastine binding to plasma membrane vesicles derived from CEM/VLB100 cells contained three ring aromatic features and one hydrophobic feature. A third pharmacophore generated with 17 inhibitors of vinblastine accumulation in P-gp expressing LLC-PK1 cells contained four hydrophobes and one hydrogen bond acceptor. A final pharmacophore was generated for inhibition of calcein accumulation in P-gp expressing LLC-PK1 cells and found to contain two hydrophobes, a ring aromatic feature, and a hydrogen bond donor. The similarity of features for the pharmacophores of P-gp inhibitors of digoxin transport and vinblastine binding suggest some commonality in their binding sites. Utilization of such models may prove to be of value for prediction of molecules that may modulate one or more P-gp binding sites.
引用
收藏
页码:964 / 973
页数:10
相关论文
共 39 条
  • [1] Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein
    Ayesh, S
    Shao, YM
    Stein, WD
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1996, 1316 (01): : 8 - 18
  • [2] Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis
    Bakken, GA
    Jurs, PC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) : 4534 - 4541
  • [3] Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
    Borgnia, MJ
    Eytan, GD
    Assaraf, YG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) : 3163 - 3171
  • [4] Chiba P, 1996, MOL PHARMACOL, V49, P1122
  • [5] Dantzig AH, 1996, CANCER RES, V56, P4171
  • [6] Identification of the cyclosporin-binding site in P-glycoprotein
    Demeule, M
    Laplante, A
    Murphy, GF
    Wenger, RM
    Béliveau, R
    [J]. BIOCHEMISTRY, 1998, 37 (51) : 18110 - 18118
  • [7] Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
    Dey, S
    Ramachandra, M
    Pastan, I
    Gottesman, MM
    Ambudkar, SV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) : 10594 - 10599
  • [8] Ecker G, 1999, MOL PHARMACOL, V56, P791
  • [9] Ekins S, 2000, IUL BIOTECH, V2, P269
  • [10] Ekins S, 1999, J PHARMACOL EXP THER, V290, P429